Press Releases

Date	Title
February 13, 2018	Oncobiologics Receives Positive Nasdaq Listing Determination CRANBURY, N.J. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (NASDAQ:ONSIW) (NASDAQ:ONSIZ) announced today that on February 13, 2018 , the Company received formal notice that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for the transfer of its
February 9, 2018	Oncobiologics Announces Term Extension of Series A Warrants CRANBURY, N.J. , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (NASDAQ:ONSIW) (NASDAQ:ONSIZ) announced today an extension to the term for exercise of its publicly traded Series A warrants (NASDAQ:ONSIW). The Series A warrants were issued as part of the units in Oncobiologics’
October 31, 2017	Oncobiologics Announces Closing of Strategic Partnership Deal with GMS Tenshi Holdings CRANBURY, N.J. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), today announced that it closed the sale of the remaining securities to GMS Tenshi Holdings Pte. Limited (“GMS Tenshi”) in the previously announced $25.0 million private placement, which builds a strategic
September 8, 2017	Oncobiologics announces strategic partnership with GMS Tenshi Holdings Pte. Limited Up to $50 million in combination of equity, warrants and license fees CRANBURY, N.J. , Sept. 08, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it entered into a Purchase Agreement on September 7, 2017 with GMS Tenshi Holdings Pte.
June 1, 2017	Oncobiologics Closes on Final Portion of $15 Million Senior Secured Note and Warrant Offering CRANBURY, N.J. , June 01, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that it has completed the
May 9, 2017	Oncobiologics to Present at the World Biosimilar Congress 2017 CRANBURY, N.J. , May 09, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced that Pankaj Mohan , Ph.D., Chairman and Chief
April 17, 2017	Oncobiologics Secures Additional Funding CRANBURY, N.J. , April 17, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that it has amended its
February 6, 2017	Oncobiologics Announces Term Extension of Series A Warrants CRANBURY, N.J. , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (Nasdaq:ONS) (Nasdaq:ONSIW), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody biosimilar therapeutics, today announced an extension to
January 10, 2017	Oncobiologics Issues Remaining Senior Secured Notes and Warrants – Raising an Aggregate $10.0 Million CRANBURY, N.J. , Jan. 10, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it closed the sale of the remaining $1.65 million senior secured notes and warrants to purchase 379,500 shares of its common stock under its previously announced Note and Warrant Purchase
December 23, 2016	Oncobiologics Issues $8.35 Million of Senior Secured Notes and Warrants to Acquire 1.9 Million Shares as part of Aggregate $10.0 Million Note and 2.3 Million Warrant Offering CRANBURY, N.J. , Dec. 23, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that it entered into a